Citigroup Inc Biovie Inc. Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.4 - $0.56 $328 - $460	-822 Reduced 30.3%	1,891 $0
Q1 2024 May 10, 2024	BUY	$0.53 - $1.89 $368 - $1,315	696 Added 34.51%	2,713 $1,000
Q4 2023 Feb 09, 2024	BUY	$1.22 - $5.24 $2,429 - $10,432	1,991 Added 7657.69%	2,017 $2,000
Q3 2023 Nov 09, 2023	SELL	$2.75 - $5.17 $2,645 - $4,973	-962 Reduced 97.37%	26 $0
Q2 2023 Aug 10, 2023	SELL	$4.09 - $8.29 $6,437 - $13,048	-1,574 Reduced 61.44%	988 $4,000
Q1 2023 May 11, 2023	BUY	$4.89 - $10.53 $2,063 - $4,443	422 Added 19.72%	2,562 $20,000
Q4 2022 Feb 09, 2023	BUY	$3.86 - $42.0 $8,260 - $89,880	2,140 New	2,140 $16,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $92M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.